The National Institute of Public Health (FHI) will not restart vaccination with the AstraZeneca vaccine for the time being.
“We will thoroughly assess whether there is a connection between the vaccines and the cases of the disease. We take note of EMA’s assessment,” the FHI’s director Camilla Stoltenberg said.
She said that the FHI will continue its investigations and assessment but says that it is too early to conclude.
Waiting for at least one week
“We will make an assessment at the end of next week,” Stoltenberg said at the press conference on Thursday night.
“The vaccination with AstraZeneca will continue to be on pause until we have a more complete picture of the situation,” Stoltenberg added.
Stoltenberg also said that the decision on March 11 to stop vaccinating with the AstraZeneca vaccine was correct.
“It is important to pause when you are notified of serious incidents,” she emphasized.
EMA recommends continued use
Earlier on Thursday, the Norwegian Medicines Agency stated that a connection between blood clots and the AstraZeneca vaccine cannot be ruled out and that it must be closely monitored.
On Thursday, the European Medicines Agency (EMA) gave the green light to the AstraZeneca vaccine’s continued use.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
I think that the The National Institute of Public Health (FHI) is being understandably cautious in light of the recent blood clotting incidents, and should not be criticised for taking such a cautious approach.